Evidence-Based Medical News

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine Orthopedics & Sports Medicine OB/GYN & Women's Health Radiology & Imaging Genetics & Precision Medicine Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Hematology Urology Ophthalmology Emergency Medicine Dermatology Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

Gallbladder Cancer

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Gallbladder Cancer

25 trials tracked for Gallbladder Cancer: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 50 citations.

25Trials tracked

1Phase 3 & 4

0Recruiting

1With published results

Phase distribution

Phase 3 1 Phase 2 21 Phase 1 1 Other / NA 2

Phase 3 Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Completed · 50 cited
Phase 2 Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed
Phase 2 MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery Completed
Phase 2 TAS-102 in Treating Advanced Biliary Tract Cancers Completed
Phase 2 Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery Completed
Phase 2 Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers Completed

Show 19 more trials

Phase 2 Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer Completed
Phase 2 S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed
Phase 2 Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Completed
Phase 2 A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers Completed
Phase 2 S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct Completed
Phase 2 M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) Completed
Phase 2 Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer Completed
Phase 2 Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors Completed
Phase 2 Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer Completed
Phase 2 Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer Completed
Phase 2 Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma Completed
Phase 2 Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC) Completed
Phase 2 Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy Completed
Phase 2 Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer Completed
Phase 2 Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery Completed
Phase 2 Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer Completed
Phase 1 A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors Completed
N/A Programs To Support You During Chemotherapy Completed
N/A A Dual Channel Supraglottic Airway Device (LMA Gastro) for Oxygenation in Patients Undergoing ERCP Completed

Showing the 25 most-cited and recently-updated of 25 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Gallbladder Cancer: what the trials found

Clinical evidence for gallbladder cancer includes several trials evaluating chemotherapy agents. Cisplatin was evaluated in two studies; however, results showed no statistically significant difference in median progression-free survival (p=0.62) or overall survival (p=0.39) [1, 5].

Capecitabine has been studied across multiple trials. One study reported a statistically significant improvement in overall survival (p=0.05) ⁹, while other studies focused on safety profiles, reporting varying numbers of Grade 3 through 5 adverse events [10, 21].

Other established interventions include Gemcitabine [13, 15], Erlotinib Hydrochloride [18, 20], and Lapatinib Ditosylate [16, 17]. Data on the specific efficacy outcomes for these agents were not reported in the provided trial set.

Capecitabine was also evaluated in a separate study where no specific outcome metrics were provided beyond its inclusion as an established intervention ²².

Recent results — preliminary, needs further review

Atezolizumab showed statistically significant improvement in progression-free survival (p=0.027), but did not show a statistically significant difference in overall survival (p=0.410) or the number of participants with adverse events (p=0.22) ².
Ramucirumab demonstrated a disease control rate of 45% ³.
M7824 showed an objective response rate of 10.7% as assessed by both independent review and investigator assessment; results varied based on PD-L1 expression levels ⁶.
TAS-102 (Trifluridine/Tipiracil Hydrochloride) was evaluated for toxicity, showing a Grade 3 or higher adverse event rate of 48.1% vs 11.1% ⁸.

For the clinician treating this condition

Cisplatin did not demonstrate statistically significant improvements in progression-free survival or overall survival in the evaluated cohorts.
Capecitabine showed a statistically significant improvement in overall survival in one trial, with various safety profiles noted across other studies.
Atezolizumab showed a statistically significant improvement in progression-free survival, though this did not translate to a significant difference in overall survival.

AI synthesis of 6 cited trials, updated Jul 6, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.